Homepage Top Section2

UB-612 is said to be the first multitope, synthetic peptide-based Covid-19 vaccine candidate. Under the terms of the deal, Aurobindo Pharma will leverage its existing development, commercial and

With the latest deal, the companies now will deliver up to 200 million doses to the US. Both firms plan to supply the full 200 million doses to

In July this year, the company revealed a potential two-pronged strategy for the treatment of Covid-19. First, preclinical cell culture experiments shown CRV431 reduced SARS-CoV-1 production of infectious

As per the EUA, the mRNA-1273 vaccine can be administered to individuals aged 18 years or older. Following the EUA, Moderna has commenced delivery of the Covid-19 vaccine

Lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), may lead to end-stage kidney disease. Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody

The randomised, controlled and double-blind study will recruit 352 patients in between 25 and 30 medical centres and hospitals in North America. The multicentre study will evaluate the

Via newly established Swedish limited liability company Roar BidCo AB, EQT IX has announced a public offer of SEK220 ($26.1) in cash per share to the shareholders of

Leqvio, a first-in-class small interfering RNA (siRNA), has been approved based on data from the ORION clinical development programme. The approval allows to use Leqvio in combination with

NBE-Therapeutics is engaged in developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies by using its immune stimulatory iADC platform. NBE-002, the company’s lead compound, is presently in